Zhixiang Jintai announced that the phase III clinical trial of the company's self-developed telicibimab injection for chronic sinusitis with nasal polyps has reached the main end, and the company submitted a marketing application for the new drug with this indication to the Drug Evaluation Center of the State Drug Administration and was accepted. This drug is a recombinant all-human anti-IL-4Rα monoclonal antibody. Its indications for seasonal allergic rhinitis in adults and moderate to severe atopic dermatitis in adults are all in the marketing application review stage, and several other indications are in clinical trials. The application is still subject to review, verification and approval, and there is uncertainty about whether it will be successfully listed and when.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.